Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib

Ying Pang,Qi Li,Zach Sergi,Guangyang Yu,Xueyu Sang,Olga Kim,Herui Wang,Alice Ranjan,Mythili Merchant,Belene Oudit,Robert W. Robey,Ferri Soheilian,Bao Tran,Felipe J. Núñez,Meili Zhang,Hua Song,Wei Zhang,Dionne Davis,Mark R. Gilbert,Michael M. Gottesman,Zhenggang Liu,Javed Khan,Craig J. Thomas,Maria G. Castro,Taranjit S. Gujral,Jing Wu

DOI: https://doi.org/10.1101/2023.06.29.547143

2024-01-02

Abstract:Isocitrate dehydrogenase (IDH)-mutant gliomas have distinctive metabolic and biological traits that may render them susceptible to targeted treatments. Here, by conducting a high-throughput drug screen, we pinpointed a specific susceptibility of IDH-mutant gliomas to zotiraciclib (ZTR). ZTR exhibited selective growth inhibition across multiple IDH-mutant glioma and models. Mechanistically, ZTR at low doses suppressed CDK9 and RNA Pol II phosphorylation in IDH-mutant cells, disrupting mitochondrial function and NAD+ production, causing oxidative stress. Integrated biochemical profiling of ZTR kinase targets and transcriptomics unveiled that ZTR-induced bioenergetic failure was linked to the suppression of PIM kinase activity. We posit that the combination of mitochondrial dysfunction and an inability to adapt to oxidative stress resulted in significant cell death upon ZTR treatment, ultimately increasing the therapeutic vulnerability of IDH-mutant gliomas. These findings prompted a clinical trial evaluating ZTR in IDH-mutant gliomas towards precision medicine ( ).

Cancer Biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the therapeutic potential of zotiraciclib (ZTR) in IDH - mutant gliomas and its mechanism of action. Specifically, through high - throughput drug screening, the researchers found that ZTR has a selective inhibitory effect on IDH - mutant glioma cells, and further explored the molecular basis of this selectivity. The study found that ZTR not only inhibits CDK9 activity, but also unexpectedly inhibits PIM kinases, leading to mitochondrial dysfunction and bioenergetic failure, thereby increasing the therapeutic vulnerability of IDH - mutant gliomas. These findings have led to the launch of the clinical trial NCT05588141, which aims to evaluate the efficacy of ZTR in patients with IDH - mutant gliomas.

### Main research contents and findings:
1. **Selective inhibition of ZTR on IDH - mutant glioma cells**:
- Through cell viability experiments, the researchers found that the half - maximal inhibitory concentration (IC50) of ZTR in IDH - mutant glioma cells was significantly lower than that in IDH - wild - type cells.
- The results of high - throughput drug screening showed that ZTR is one of the few drugs that can effectively kill cells and penetrate the blood - brain barrier.

2. **Efficacy of ZTR in in - vivo models**:
- In the mouse model, ZTR treatment significantly prolonged the survival time of mice with IDH - mutant gliomas, while having no significant impact on the survival time of IDH - wild - type gliomas.
- Pharmacokinetic analysis showed that ZTR can inhibit the phosphorylation of CDK9 and induce DNA damage, supporting its ability to penetrate the blood - brain barrier.

3. **Cell - cycle arrest and metabolic changes induced by ZTR**:
- After treatment with low - dose ZTR, IDH - mutant glioma cells showed cell - cycle arrest, mitochondrial dysfunction, and increased oxidative stress.
- RNA sequencing and gene - expression analysis indicated that after ZTR treatment, the NAD+ level in IDH - mutant cells decreased, and the activity of mitochondrial complex I was inhibited, resulting in a reduction in ATP production.

4. **Inhibitory effect of ZTR on PIM kinases**:
- The study found that ZTR inhibits not only CDK9, but also PIM1 and PIM3 kinases, which may be a key mechanism by which ZTR induces mitochondrial dysfunction.
- Treating cells with the PIM kinase inhibitor AZD1208 yielded results similar to those of ZTR, further validating the importance of PIM kinases in IDH - mutant gliomas.

### Conclusion:
This study reveals that ZTR increases the therapeutic vulnerability of IDH - mutant glioma cells by inhibiting CDK9 and PIM kinases, leading to mitochondrial dysfunction and bioenergetic failure. These findings provide new ideas for the development of precision therapies for IDH - mutant gliomas and promote the progress of related clinical trials.